Summary: Biotalys (Euronext: BTLS) has announced a strategic refocus to prioritize its most advanced protein-based biocontrol programs, including EVOCA NG and BioFun-6. The initiative is designed to reduce total cash burn by €20 million through 2028, streamlining operations and right-sizing the organization to accelerate the path toward commercializing its precision biocontrol pipeline.
Biotalys Announces Strategic Refocus to Prioritize Core Biofungicide Programs
Ghent, BELGIUM — February 09, 2026
Biotalys today announced its intention to proceed with a strategic refocus designed to concentrate resources on its highest-priority programs and streamline operations. As part of this initiative, the company intends to right-size its organizational structure, including a workforce reduction of 30 employees, and suspend early-stage activities to reduce operating expenses.
The initiative is expected to result in an estimated reduction in total cash burn of €20 million until the end of 2028. The company intends to prioritize the development and regulatory advancement of its lead biofungicide assets, focusing commercial preparation on markets with the highest near-term potential.
- Lead Assets: Priority focus on the advanced biofungicide programs EVOCA NG and BioFun-6.
- Partnered Programs: Continued support for BioFun-7 (Gates Foundation) and BioIns-2 (insecticide with Syngenta).
- Manufacturing & Post-Harvest: Leveraging partnerships with 21st.BIO for cost-competitive production and AgroFresh for the post-harvest market.
- Commercial Timeline: EVOCA NG is targeted for a 2029 launch in the USA and 2030 in Europe, addressing a $1.1 billion combined market.
“It is imperative that we deploy capital where it creates the greatest impact,” said Kevin Helash, CEO of Biotalys. “A narrowing of the focus to our core assets and most advanced programs aims to strengthen our ability to deliver innovative, sustainable crop protection solutions to growers and advance our path to long-term value creation.”
The company confirmed its cash runway into May 2026 and is currently in discussions with investors regarding potential financing options to support the sharpened portfolio. Following the recent EPA approval of first-generation EVOCA, Biotalys anticipates a significantly shorter regulatory review process for EVOCA NG, as it utilizes the same active ingredient.
About EVOCA™
EVOCA helps safely control Botrytis (grey mold) and powdery mildew. EVOCA NG is expected to be the company’s first commercial biofungicide, utilizing the novel AGROBODY™ technology platform to bridge the efficacy of chemistry with the safety of biologicals.
About Biotalys
Biotalys is an AgTech company developing precision biocontrol solutions based on proteins. Founded in 2013 as a spin-off from VIB, the company is listed on Euronext Brussels and is based in the biotech cluster in Ghent, Belgium.
Leave a Reply